🇺🇸 FDA
Pipeline program

tacrolimus

ACN-PRT-AD-12-1

Approved small_molecule completed

Quick answer

tacrolimus for Moderate/Severe Atopic Dermatitis is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Moderate/Severe Atopic Dermatitis
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials